Company intelligence / Profile preview

Oblato, Inc.

New Jersey, United Statesprnewswire.com ↗

Ownership: Private
Development stage: Phase 3

Overview

Oblato’s lead program, OKN-007, is in ongoing clinical development for brain cancers. The injectable formulation has completed patient enrollment in a Phase 2 trial for recurrent GBM in combination with temozolomide. An oral formulation entered Phase 1 trials for recurrent high-grade glioma patients as of April 2023. The company has received rare pediatric disease and fast track designations from the FDA for DIPG. Some patients are still under treatment or follow-up from previous studies.

Therapeutic areas: Oncology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

OKN-007

Partnerships

Academic/clinical partnerships include multiple U.S. institutions such as Henry Ford Health System participating in clinical trials; original licensing agreement with Oklahoma Medical Research Foundation (OMRF) for rights to OKN‑007. No major pharma co-development deals disclosed.

Beyond the preview

Go deeper on Oblato, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Oblato, Inc..

Explore the full profile